Selected research
Industry Research
Patient-Derived Disease Modeling Platform Industry Research Report 2026
Market perspective
The global Patient-Derived Disease Modeling Platform market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Patient-Derived Disease Modeling Platform market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Patient-Derived Disease Modeling Platform market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Patient-Derived Disease Modeling Platform market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Patient-Derived Disease Modeling Platform include Evotec, Pharmaron, The Jackson Laboratory, Champions Oncology, ATCC, Molecular Devices, FUJIFILM Cellular Dynamics, REPROCELL and Ncardia, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Patient-Derived Disease Modeling Platform market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Patient-Derived Disease Modeling Platform.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Patient-Derived Disease Modeling Platform Market by Company
Evotec
Pharmaron
The Jackson Laboratory
Champions Oncology
ATCC
Molecular Devices
FUJIFILM Cellular Dynamics
REPROCELL
Ncardia
Axol Bioscience
MIMETAS
Oncodesign Services
GemPharmatech
Shanghai Model Organisms Center
Medicilon
InnoSer
Certis Oncology Solutions
Curi Bio
Newcells Biotech
K2 Oncology
Pixlbio
Charles River Laboratories
Crown Bioscience
WuXi AppTec
Patient-Derived Disease Modeling Platform Segment by Type
Patient-Derived Primary Cell Models
Patient-Derived iPSC Models
Patient-Derived Organoid Models
Patient-Derived Tissue Explant Models
Patient-Derived Organ-on-a-Chip Models
Patient-Derived Xenograft Models
Patient-Derived Disease Modeling Platform Segment by Application
Disease Mechanism Research
Target Discovery and Validation
Drug Screening and Lead Optimization
Efficacy and Resistance Evaluation
Safety and Toxicology Assessment
Precision Medicine and Biomarker Research
Patient-Derived Disease Modeling Platform Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Patient-Derived Disease Modeling Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Patient-Derived Disease Modeling Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Patient-Derived Disease Modeling Platform.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Patient-Derived Disease Modeling Platform companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Patient-Derived Disease Modeling Platform Market Size by Type (2021-2026) & (US$ Million)
Table 6. Global Patient-Derived Disease Modeling Platform Revenue Market Share by Type (2021-2026)
Table 7. Global Patient-Derived Disease Modeling Platform Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 8. Global Patient-Derived Disease Modeling Platform Revenue Market Share by Type (2027-2032)
Table 9. Global Patient-Derived Disease Modeling Platform Market Size by Application (2021-2026) & (US$ Million)
Table 10. Global Patient-Derived Disease Modeling Platform Revenue Market Share by Application (2021-2026)
Table 11. Global Patient-Derived Disease Modeling Platform Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 12. Global Patient-Derived Disease Modeling Platform Revenue Market Share by Application (2027-2032)
Table 13. Global Patient-Derived Disease Modeling Platform Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 14. Global Patient-Derived Disease Modeling Platform Market Size by Region (2021-2026) & (US$ Million)
Table 15. Global Patient-Derived Disease Modeling Platform Market Share by Region (2021-2026)
Table 16. Global Patient-Derived Disease Modeling Platform Forecasted Market Size by Region (2027-2032) & (US$ Million)
Table 17. Global Patient-Derived Disease Modeling Platform Market Share by Region (2027-2032)
Table 18. Patient-Derived Disease Modeling Platform Industry Trends
Table 19. Patient-Derived Disease Modeling Platform Industry Drivers
Table 20. Patient-Derived Disease Modeling Platform Industry Opportunities and Challenges
Table 21. Patient-Derived Disease Modeling Platform Market Restraints
Table 22. Global Top Patient-Derived Disease Modeling Platform Players by Revenue (US$ Million) & (2021-2026)
Table 23. Global Patient-Derived Disease Modeling Platform Revenue Market Share by Players (2021-2026)
Table 24. Global Patient-Derived Disease Modeling Platform Industry Players Ranking, 2024 VS 2025 VS 2026
Table 25. Global Key Players of Patient-Derived Disease Modeling Platform, Headquarters and Area Served
Table 26. Global Patient-Derived Disease Modeling Platform Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Patient-Derived Disease Modeling Platform by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. North America Patient-Derived Disease Modeling Platform Market Size by Country (2021-2026) & (US$ Million)
Table 32. North America Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032) & (US$ Million)
Table 33. Europe Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Europe Patient-Derived Disease Modeling Platform Market Size by Country (2021-2026) & (US$ Million)
Table 35. Europe Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032) & (US$ Million)
Table 36. Asia Pacific Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Asia Pacific Patient-Derived Disease Modeling Platform Market Size by Region (2021-2026) & (US$ Million)
Table 38. Asia Pacific Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032) & (US$ Million)
Table 39. South America Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 40. South America Patient-Derived Disease Modeling Platform Market Size by Country (2021-2026) & (US$ Million)
Table 41. South America Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032) & (US$ Million)
Table 42. Middle East & Africa Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Middle East & Africa Patient-Derived Disease Modeling Platform Market Size by Country (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032) & (US$ Million)
Table 45. Evotec Company Information
Table 46. Evotec Business Overview
Table 47. Evotec Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 48. Evotec Patient-Derived Disease Modeling Platform Product Portfolio
Table 49. Evotec Recent Developments
Table 50. Pharmaron Company Information
Table 51. Pharmaron Business Overview
Table 52. Pharmaron Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 53. Pharmaron Patient-Derived Disease Modeling Platform Product Portfolio
Table 54. Pharmaron Recent Developments
Table 55. The Jackson Laboratory Company Information
Table 56. The Jackson Laboratory Business Overview
Table 57. The Jackson Laboratory Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 58. The Jackson Laboratory Patient-Derived Disease Modeling Platform Product Portfolio
Table 59. The Jackson Laboratory Recent Developments
Table 60. Champions Oncology Company Information
Table 61. Champions Oncology Business Overview
Table 62. Champions Oncology Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 63. Champions Oncology Patient-Derived Disease Modeling Platform Product Portfolio
Table 64. Champions Oncology Recent Developments
Table 65. ATCC Company Information
Table 66. ATCC Business Overview
Table 67. ATCC Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 68. ATCC Patient-Derived Disease Modeling Platform Product Portfolio
Table 69. ATCC Recent Developments
Table 70. Molecular Devices Company Information
Table 71. Molecular Devices Business Overview
Table 72. Molecular Devices Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 73. Molecular Devices Patient-Derived Disease Modeling Platform Product Portfolio
Table 74. Molecular Devices Recent Developments
Table 75. FUJIFILM Cellular Dynamics Company Information
Table 76. FUJIFILM Cellular Dynamics Business Overview
Table 77. FUJIFILM Cellular Dynamics Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 78. FUJIFILM Cellular Dynamics Patient-Derived Disease Modeling Platform Product Portfolio
Table 79. FUJIFILM Cellular Dynamics Recent Developments
Table 80. REPROCELL Company Information
Table 81. REPROCELL Business Overview
Table 82. REPROCELL Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 83. REPROCELL Patient-Derived Disease Modeling Platform Product Portfolio
Table 84. REPROCELL Recent Developments
Table 85. Ncardia Company Information
Table 86. Ncardia Business Overview
Table 87. Ncardia Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 88. Ncardia Patient-Derived Disease Modeling Platform Product Portfolio
Table 89. Ncardia Recent Developments
Table 90. Axol Bioscience Company Information
Table 91. Axol Bioscience Business Overview
Table 92. Axol Bioscience Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 93. Axol Bioscience Patient-Derived Disease Modeling Platform Product Portfolio
Table 94. Axol Bioscience Recent Developments
Table 95. MIMETAS Company Information
Table 96. MIMETAS Business Overview
Table 97. MIMETAS Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 98. MIMETAS Patient-Derived Disease Modeling Platform Product Portfolio
Table 99. MIMETAS Recent Developments
Table 100. Oncodesign Services Company Information
Table 101. Oncodesign Services Business Overview
Table 102. Oncodesign Services Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 103. Oncodesign Services Patient-Derived Disease Modeling Platform Product Portfolio
Table 104. Oncodesign Services Recent Developments
Table 105. GemPharmatech Company Information
Table 106. GemPharmatech Business Overview
Table 107. GemPharmatech Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 108. GemPharmatech Patient-Derived Disease Modeling Platform Product Portfolio
Table 109. GemPharmatech Recent Developments
Table 110. Shanghai Model Organisms Center Company Information
Table 111. Shanghai Model Organisms Center Business Overview
Table 112. Shanghai Model Organisms Center Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 113. Shanghai Model Organisms Center Patient-Derived Disease Modeling Platform Product Portfolio
Table 114. Shanghai Model Organisms Center Recent Developments
Table 115. Medicilon Company Information
Table 116. Medicilon Business Overview
Table 117. Medicilon Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 118. Medicilon Patient-Derived Disease Modeling Platform Product Portfolio
Table 119. Medicilon Recent Developments
Table 120. InnoSer Company Information
Table 121. InnoSer Business Overview
Table 122. InnoSer Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 123. InnoSer Patient-Derived Disease Modeling Platform Product Portfolio
Table 124. InnoSer Recent Developments
Table 125. Certis Oncology Solutions Company Information
Table 126. Certis Oncology Solutions Business Overview
Table 127. Certis Oncology Solutions Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 128. Certis Oncology Solutions Patient-Derived Disease Modeling Platform Product Portfolio
Table 129. Certis Oncology Solutions Recent Developments
Table 130. Curi Bio Company Information
Table 131. Curi Bio Business Overview
Table 132. Curi Bio Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 133. Curi Bio Patient-Derived Disease Modeling Platform Product Portfolio
Table 134. Curi Bio Recent Developments
Table 135. Newcells Biotech Company Information
Table 136. Newcells Biotech Business Overview
Table 137. Newcells Biotech Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 138. Newcells Biotech Patient-Derived Disease Modeling Platform Product Portfolio
Table 139. Newcells Biotech Recent Developments
Table 140. K2 Oncology Company Information
Table 141. K2 Oncology Business Overview
Table 142. K2 Oncology Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 143. K2 Oncology Patient-Derived Disease Modeling Platform Product Portfolio
Table 144. K2 Oncology Recent Developments
Table 145. Pixlbio Company Information
Table 146. Pixlbio Business Overview
Table 147. Pixlbio Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 148. Pixlbio Patient-Derived Disease Modeling Platform Product Portfolio
Table 149. Pixlbio Recent Developments
Table 150. Charles River Laboratories Company Information
Table 151. Charles River Laboratories Business Overview
Table 152. Charles River Laboratories Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 153. Charles River Laboratories Patient-Derived Disease Modeling Platform Product Portfolio
Table 154. Charles River Laboratories Recent Developments
Table 155. Crown Bioscience Company Information
Table 156. Crown Bioscience Business Overview
Table 157. Crown Bioscience Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 158. Crown Bioscience Patient-Derived Disease Modeling Platform Product Portfolio
Table 159. Crown Bioscience Recent Developments
Table 160. WuXi AppTec Company Information
Table 161. WuXi AppTec Business Overview
Table 162. WuXi AppTec Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026) & (US$ Million)
Table 163. WuXi AppTec Patient-Derived Disease Modeling Platform Product Portfolio
Table 164. WuXi AppTec Recent Developments
Table 165. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Patient-Derived Disease Modeling Platform Product Image
Figure 5. Global Patient-Derived Disease Modeling Platform Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 6. Global Patient-Derived Disease Modeling Platform Market Share by Type: 2025 VS 2032
Figure 7. Patient-Derived Primary Cell Models Product
Figure 8. Patient-Derived iPSC Models Product
Figure 9. Patient-Derived Organoid Models Product
Figure 10. Patient-Derived Tissue Explant Models Product
Figure 11. Patient-Derived Organ-on-a-Chip Models Product
Figure 12. Patient-Derived Xenograft Models Product
Figure 13. Global Patient-Derived Disease Modeling Platform Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 14. Global Patient-Derived Disease Modeling Platform Market Share by Application: 2025 VS 2032
Figure 15. Disease Mechanism Research Product
Figure 16. Target Discovery and Validation Product
Figure 17. Drug Screening and Lead Optimization Product
Figure 18. Efficacy and Resistance Evaluation Product
Figure 19. Safety and Toxicology Assessment Product
Figure 20. Precision Medicine and Biomarker Research Product
Figure 21. Global Patient-Derived Disease Modeling Platform Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 22. Global Patient-Derived Disease Modeling Platform Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 23. Global Patient-Derived Disease Modeling Platform Market Share by Region: 2025 VS 2032
Figure 24. Global Patient-Derived Disease Modeling Platform Market Share by Players in 2025
Figure 25. Global Patient-Derived Disease Modeling Platform Manufacturers Established Date
Figure 26. Global Top 5 and 10 Patient-Derived Disease Modeling Platform Players Market Share by Revenue in 2025
Figure 27. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 28. North America Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 29. North America Patient-Derived Disease Modeling Platform Market Share by Country (2021-2032)
Figure 30. United States Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. Canada Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 32. Mexico Patient-Derived Disease Modeling Platform Market Share by Country (2021-2032)
Figure 33. Europe Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 34. Europe Patient-Derived Disease Modeling Platform Market Share by Country (2021-2032)
Figure 35. Germany Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 36. France Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 37. U.K. Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 38. Italy Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 39. Spain Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 40. Russia Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 41. Netherlands Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 42. Nordic Countries Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 43. Asia-Pacific Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 44. Asia-Pacific Patient-Derived Disease Modeling Platform Market Share by Country (2021-2032)
Figure 45. China Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 46. Japan Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 47. South Korea Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 48. India Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 49. India Patient-Derived Disease Modeling Platform Market Share by Country (2021-2032)
Figure 50. Australia Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 51. China Taiwan Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 52. Southeast Asia Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 53. South America Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 54. South America Patient-Derived Disease Modeling Platform Market Share by Country (2021-2032)
Figure 55. Brazil Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 56. Argentina Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 57. Chile Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 58. Colombia Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 59. Peru Patient-Derived Disease Modeling Platform Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 60. Evotec Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 61. Pharmaron Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 62. The Jackson Laboratory Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 63. Champions Oncology Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 64. ATCC Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 65. Molecular Devices Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 66. FUJIFILM Cellular Dynamics Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 67. REPROCELL Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 68. Ncardia Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 69. Axol Bioscience Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 70. MIMETAS Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 71. Oncodesign Services Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 72. GemPharmatech Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 73. Shanghai Model Organisms Center Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 74. Medicilon Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 75. InnoSer Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 76. Certis Oncology Solutions Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 77. Curi Bio Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 78. Newcells Biotech Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 79. K2 Oncology Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 80. Pixlbio Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 81. Charles River Laboratories Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 82. Crown Bioscience Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Figure 83. WuXi AppTec Revenue Growth Rate in Patient-Derived Disease Modeling Platform Business (2021-2026)
Scope & coverage.
Types
- Patient-Derived Primary Cell Models
- Patient-Derived iPSC Models
- Patient-Derived Organoid Models
- Patient-Derived Tissue Explant Models
- Patient-Derived Organ-on-a-Chip Models
- Patient-Derived Xenograft Models
Applications
- Disease Mechanism Research
- Target Discovery and Validation
- Drug Screening and Lead Optimization
- Efficacy and Resistance Evaluation
- Safety and Toxicology Assessment
- Precision Medicine and Biomarker Research
Companies covered
- Evotec
- Pharmaron
- The Jackson Laboratory
- Champions Oncology
- ATCC
- Molecular Devices
- FUJIFILM Cellular Dynamics
- REPROCELL
- Ncardia
- Axol Bioscience
- MIMETAS
- Oncodesign Services
- GemPharmatech
- Shanghai Model Organisms Center
- Medicilon
- InnoSer
- Certis Oncology Solutions
- Curi Bio
- Newcells Biotech
- K2 Oncology
- Pixlbio
- Charles River Laboratories
- Crown Bioscience
- WuXi AppTec
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Patient-Derived Disease Modeling Platform by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Patient-Derived Primary Cell Models
- 2.2.3 Patient-Derived iPSC Models
- 2.2.4 Patient-Derived Organoid Models
- 2.2.5 Patient-Derived Tissue Explant Models
- 2.2.6 Patient-Derived Organ-on-a-Chip Models
- 2.2.7 Patient-Derived Xenograft Models
- 2.3 Patient-Derived Disease Modeling Platform by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Disease Mechanism Research
- 2.3.3 Target Discovery and Validation
- 2.3.4 Drug Screening and Lead Optimization
- 2.3.5 Efficacy and Resistance Evaluation
- 2.3.6 Safety and Toxicology Assessment
- 2.3.7 Precision Medicine and Biomarker Research
- 2.4 Assumptions and Limitations
3 Patient-Derived Disease Modeling Platform Breakdown Data by Type
- 3.1 Global Patient-Derived Disease Modeling Platform Historic Market Size by Type (2021-2026)
- 3.2 Global Patient-Derived Disease Modeling Platform Forecasted Market Size by Type (2027-2032)
4 Patient-Derived Disease Modeling Platform Breakdown Data by Application
- 4.1 Global Patient-Derived Disease Modeling Platform Historic Market Size by Application (2021-2026)
- 4.2 Global Patient-Derived Disease Modeling Platform Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Patient-Derived Disease Modeling Platform Market Perspective (2021-2032)
- 5.2 Global Patient-Derived Disease Modeling Platform Growth Trends by Region
- 5.2.1 Global Patient-Derived Disease Modeling Platform Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Patient-Derived Disease Modeling Platform Historic Market Size by Region (2021-2026)
- 5.2.3 Patient-Derived Disease Modeling Platform Forecasted Market Size by Region (2027-2032)
- 5.3 Patient-Derived Disease Modeling Platform Market Dynamics
- 5.3.1 Patient-Derived Disease Modeling Platform Industry Trends
- 5.3.2 Patient-Derived Disease Modeling Platform Market Drivers
- 5.3.3 Patient-Derived Disease Modeling Platform Market Challenges
- 5.3.4 Patient-Derived Disease Modeling Platform Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Patient-Derived Disease Modeling Platform Players by Revenue
- 6.1.1 Global Top Patient-Derived Disease Modeling Platform Players by Revenue (2021-2026)
- 6.1.2 Global Patient-Derived Disease Modeling Platform Revenue Market Share by Players (2021-2026)
- 6.2 Global Patient-Derived Disease Modeling Platform Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Patient-Derived Disease Modeling Platform Head Office and Area Served
- 6.4 Global Patient-Derived Disease Modeling Platform Players, Product Type & Application
- 6.5 Global Patient-Derived Disease Modeling Platform Manufacturers Established Date
- 6.6 Global Patient-Derived Disease Modeling Platform Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Patient-Derived Disease Modeling Platform Market Size (2021-2032)
- 7.2 North America Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Patient-Derived Disease Modeling Platform Market Size by Country (2021-2026)
- 7.4 North America Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Patient-Derived Disease Modeling Platform Market Size (2021-2032)
- 8.2 Europe Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Patient-Derived Disease Modeling Platform Market Size by Country (2021-2026)
- 8.4 Europe Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Patient-Derived Disease Modeling Platform Market Size (2021-2032)
- 9.2 Asia-Pacific Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Patient-Derived Disease Modeling Platform Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Patient-Derived Disease Modeling Platform Market Size (2021-2032)
- 10.2 South America Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Patient-Derived Disease Modeling Platform Market Size by Country (2021-2026)
- 10.4 South America Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Patient-Derived Disease Modeling Platform Market Size (2021-2032)
- 11.2 Middle East & Africa Patient-Derived Disease Modeling Platform Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Patient-Derived Disease Modeling Platform Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Patient-Derived Disease Modeling Platform Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Evotec
- 12.1.1 Evotec Company Information
- 12.1.2 Evotec Business Overview
- 12.1.3 Evotec Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.1.4 Evotec Patient-Derived Disease Modeling Platform Product Portfolio
- 12.1.5 Evotec Recent Developments
- 12.2 Pharmaron
- 12.2.1 Pharmaron Company Information
- 12.2.2 Pharmaron Business Overview
- 12.2.3 Pharmaron Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.2.4 Pharmaron Patient-Derived Disease Modeling Platform Product Portfolio
- 12.2.5 Pharmaron Recent Developments
- 12.3 The Jackson Laboratory
- 12.3.1 The Jackson Laboratory Company Information
- 12.3.2 The Jackson Laboratory Business Overview
- 12.3.3 The Jackson Laboratory Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.3.4 The Jackson Laboratory Patient-Derived Disease Modeling Platform Product Portfolio
- 12.3.5 The Jackson Laboratory Recent Developments
- 12.4 Champions Oncology
- 12.4.1 Champions Oncology Company Information
- 12.4.2 Champions Oncology Business Overview
- 12.4.3 Champions Oncology Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.4.4 Champions Oncology Patient-Derived Disease Modeling Platform Product Portfolio
- 12.4.5 Champions Oncology Recent Developments
- 12.5 ATCC
- 12.5.1 ATCC Company Information
- 12.5.2 ATCC Business Overview
- 12.5.3 ATCC Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.5.4 ATCC Patient-Derived Disease Modeling Platform Product Portfolio
- 12.5.5 ATCC Recent Developments
- 12.6 Molecular Devices
- 12.6.1 Molecular Devices Company Information
- 12.6.2 Molecular Devices Business Overview
- 12.6.3 Molecular Devices Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.6.4 Molecular Devices Patient-Derived Disease Modeling Platform Product Portfolio
- 12.6.5 Molecular Devices Recent Developments
- 12.7 FUJIFILM Cellular Dynamics
- 12.7.1 FUJIFILM Cellular Dynamics Company Information
- 12.7.2 FUJIFILM Cellular Dynamics Business Overview
- 12.7.3 FUJIFILM Cellular Dynamics Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.7.4 FUJIFILM Cellular Dynamics Patient-Derived Disease Modeling Platform Product Portfolio
- 12.7.5 FUJIFILM Cellular Dynamics Recent Developments
- 12.8 REPROCELL
- 12.8.1 REPROCELL Company Information
- 12.8.2 REPROCELL Business Overview
- 12.8.3 REPROCELL Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.8.4 REPROCELL Patient-Derived Disease Modeling Platform Product Portfolio
- 12.8.5 REPROCELL Recent Developments
- 12.9 Ncardia
- 12.9.1 Ncardia Company Information
- 12.9.2 Ncardia Business Overview
- 12.9.3 Ncardia Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.9.4 Ncardia Patient-Derived Disease Modeling Platform Product Portfolio
- 12.9.5 Ncardia Recent Developments
- 12.10 Axol Bioscience
- 12.10.1 Axol Bioscience Company Information
- 12.10.2 Axol Bioscience Business Overview
- 12.10.3 Axol Bioscience Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.10.4 Axol Bioscience Patient-Derived Disease Modeling Platform Product Portfolio
- 12.10.5 Axol Bioscience Recent Developments
- 12.11 MIMETAS
- 12.11.1 MIMETAS Company Information
- 12.11.2 MIMETAS Business Overview
- 12.11.3 MIMETAS Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.11.4 MIMETAS Patient-Derived Disease Modeling Platform Product Portfolio
- 12.11.5 MIMETAS Recent Developments
- 12.12 Oncodesign Services
- 12.12.1 Oncodesign Services Company Information
- 12.12.2 Oncodesign Services Business Overview
- 12.12.3 Oncodesign Services Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.12.4 Oncodesign Services Patient-Derived Disease Modeling Platform Product Portfolio
- 12.12.5 Oncodesign Services Recent Developments
- 12.13 GemPharmatech
- 12.13.1 GemPharmatech Company Information
- 12.13.2 GemPharmatech Business Overview
- 12.13.3 GemPharmatech Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.13.4 GemPharmatech Patient-Derived Disease Modeling Platform Product Portfolio
- 12.13.5 GemPharmatech Recent Developments
- 12.14 Shanghai Model Organisms Center
- 12.14.1 Shanghai Model Organisms Center Company Information
- 12.14.2 Shanghai Model Organisms Center Business Overview
- 12.14.3 Shanghai Model Organisms Center Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.14.4 Shanghai Model Organisms Center Patient-Derived Disease Modeling Platform Product Portfolio
- 12.14.5 Shanghai Model Organisms Center Recent Developments
- 12.15 Medicilon
- 12.15.1 Medicilon Company Information
- 12.15.2 Medicilon Business Overview
- 12.15.3 Medicilon Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.15.4 Medicilon Patient-Derived Disease Modeling Platform Product Portfolio
- 12.15.5 Medicilon Recent Developments
- 12.16 InnoSer
- 12.16.1 InnoSer Company Information
- 12.16.2 InnoSer Business Overview
- 12.16.3 InnoSer Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.16.4 InnoSer Patient-Derived Disease Modeling Platform Product Portfolio
- 12.16.5 InnoSer Recent Developments
- 12.17 Certis Oncology Solutions
- 12.17.1 Certis Oncology Solutions Company Information
- 12.17.2 Certis Oncology Solutions Business Overview
- 12.17.3 Certis Oncology Solutions Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.17.4 Certis Oncology Solutions Patient-Derived Disease Modeling Platform Product Portfolio
- 12.17.5 Certis Oncology Solutions Recent Developments
- 12.18 Curi Bio
- 12.18.1 Curi Bio Company Information
- 12.18.2 Curi Bio Business Overview
- 12.18.3 Curi Bio Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.18.4 Curi Bio Patient-Derived Disease Modeling Platform Product Portfolio
- 12.18.5 Curi Bio Recent Developments
- 12.19 Newcells Biotech
- 12.19.1 Newcells Biotech Company Information
- 12.19.2 Newcells Biotech Business Overview
- 12.19.3 Newcells Biotech Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.19.4 Newcells Biotech Patient-Derived Disease Modeling Platform Product Portfolio
- 12.19.5 Newcells Biotech Recent Developments
- 12.20 K2 Oncology
- 12.20.1 K2 Oncology Company Information
- 12.20.2 K2 Oncology Business Overview
- 12.20.3 K2 Oncology Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.20.4 K2 Oncology Patient-Derived Disease Modeling Platform Product Portfolio
- 12.20.5 K2 Oncology Recent Developments
- 12.21 Pixlbio
- 12.21.1 Pixlbio Company Information
- 12.21.2 Pixlbio Business Overview
- 12.21.3 Pixlbio Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.21.4 Pixlbio Patient-Derived Disease Modeling Platform Product Portfolio
- 12.21.5 Pixlbio Recent Developments
- 12.22 Charles River Laboratories
- 12.22.1 Charles River Laboratories Company Information
- 12.22.2 Charles River Laboratories Business Overview
- 12.22.3 Charles River Laboratories Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.22.4 Charles River Laboratories Patient-Derived Disease Modeling Platform Product Portfolio
- 12.22.5 Charles River Laboratories Recent Developments
- 12.23 Crown Bioscience
- 12.23.1 Crown Bioscience Company Information
- 12.23.2 Crown Bioscience Business Overview
- 12.23.3 Crown Bioscience Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.23.4 Crown Bioscience Patient-Derived Disease Modeling Platform Product Portfolio
- 12.23.5 Crown Bioscience Recent Developments
- 12.24 WuXi AppTec
- 12.24.1 WuXi AppTec Company Information
- 12.24.2 WuXi AppTec Business Overview
- 12.24.3 WuXi AppTec Revenue in Patient-Derived Disease Modeling Platform Business (2021-2026)
- 12.24.4 WuXi AppTec Patient-Derived Disease Modeling Platform Product Portfolio
- 12.24.5 WuXi AppTec Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst